thiopental ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
hypnotics, barbituric acid derivatives 2633 76-75-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pentothal
  • thiopental sodium
  • thiopental
  • thiomebumal
  • thionembutal
  • pentothiobarbital
A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.
  • Molecular weight: 242.34
  • Formula: C11H18N2O2S
  • CLOGP: 2.98
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 58.20
  • ALOGS: -3.78
  • ROTB: 4

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 20.63 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.14 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
None FDA ABBOTT

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Status epilepticus 142.62 60.95 42 1958 13364 50589760
Diabetes insipidus 137.70 60.95 29 1971 2335 50600789
Renal ischaemia 129.14 60.95 22 1978 560 50602564
Breast cancer recurrent 123.93 60.95 29 1971 3779 50599345
PCO2 increased 114.31 60.95 22 1978 1121 50602003
PO2 increased 108.59 60.95 20 1980 802 50602322
Foetal death 101.93 60.95 29 1971 8151 50594973
Blood pH decreased 97.54 60.95 22 1978 2433 50600691
Oxygen saturation abnormal 95.44 60.95 22 1978 2680 50600444
Blood bicarbonate decreased 95.26 60.95 22 1978 2703 50600421
Left ventricular dysfunction 86.31 60.95 27 1973 10479 50592645
Blood magnesium decreased 68.51 60.95 23 1977 11137 50591987
Exposure during pregnancy 67.95 60.95 48 1952 120967 50482157
Maternal exposure during pregnancy 66.62 60.95 53 1947 159725 50443399

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intensive care unit acquired weakness 110.22 55.32 21 1265 922 29572319
Status epilepticus 108.23 55.32 33 1253 10761 29562480
Drug ineffective 90.09 55.32 93 1193 363077 29210164
Hepatitis fulminant 58.42 55.32 16 1270 3555 29569686

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Status epilepticus 210.49 44.34 67 3189 21596 64473880
Diabetes insipidus 167.12 44.34 40 3216 4481 64490995
Intensive care unit acquired weakness 145.45 44.34 30 3226 1697 64493779
Drug ineffective 125.58 44.34 180 3076 840067 63655409
Renal ischaemia 110.07 44.34 22 3234 1061 64494415
Foetal death 104.06 44.34 29 3227 5901 64489575
PCO2 increased 100.61 44.34 22 3234 1645 64493831
PO2 increased 91.77 44.34 20 3236 1472 64494004
Blood pH decreased 84.01 44.34 23 3233 4379 64491097
Oxygen saturation abnormal 83.95 44.34 22 3234 3549 64491927
Blood bicarbonate decreased 81.91 44.34 23 3233 4806 64490670
Multiple-drug resistance 79.43 44.34 24 3232 6478 64488998
Maternal exposure during pregnancy 76.65 44.34 52 3204 95832 64399644
Exposure during pregnancy 68.99 44.34 45 3211 77630 64417846
Left ventricular dysfunction 67.15 44.34 27 3229 16927 64478549
Malabsorption 65.79 44.34 19 3237 4384 64491092
Blood magnesium decreased 58.04 44.34 23 3233 13882 64481594
Hepatitis fulminant 51.07 44.34 17 3239 6257 64489219
Off label use 49.13 44.34 102 3154 632704 63862772
Electroencephalogram abnormal 45.97 44.34 15 3241 5188 64490288

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N01AF03 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, GENERAL
Barbiturates, plain
ATC N05CA19 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Barbiturates, plain
MeSH PA D000777 Anesthetics
MeSH PA D018686 Anesthetics, Intravenous
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:38877 intravenous anesthetics
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:35717 hypnotics
CHEBI has role CHEBI:78298 environmental contaminants
CHEBI has role CHEBI:88188 allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
General anesthesia indication 50697003
Benign intracranial hypertension indication 68267002 DOID:11459
Epilepsy indication 84757009 DOID:1826
Narcoanalysis indication 302683009
Cerebral ischemia off-label use 287731003
Hypoxia of brain off-label use 389088001
Chronic disease of respiratory system contraindication 17097001
Shock contraindication 27942005
Myxedema contraindication 43153006 DOID:11634
Uremia contraindication 44730006 DOID:4676
Low blood pressure contraindication 45007003
Variegate porphyria contraindication 58275005 DOID:4346
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Acute disease of cardiovascular system contraindication 128487001
Asthma contraindication 195967001 DOID:2841
Acute intermittent porphyria contraindication 234422006 DOID:3890
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Primary adrenocortical insufficiency contraindication 373662000




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Cats Anesthesia in short to moderately long surgical procedures Indication
Dogs Anesthesia in short to moderately long surgical procedures Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Combuthal Powder Bimeda Animal Health Limited 2
Sodium Thiopental Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.46 acidic
pKa2 11.46 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
GABA-A receptor; anion channel Ion channel IC50 4.53 CHEMBL
Potassium voltage-gated channel subfamily C member 4 Ion channel GATING INHIBITOR IC50 4 IUPHAR

External reference:

IDSource
4018713 VUID
N0000179744 NUI
D00714 KEGG_DRUG
71-73-8 SECONDARY_CAS_RN
4018713 VANDF
4019945 VANDF
C0039925 UMLSCUI
CHEBI:102166 CHEBI
EDP PDB_CHEM_ID
CHEMBL441 ChEMBL_ID
DB00599 DRUGBANK_ID
CHEMBL738 ChEMBL_ID
D013874 MESH_DESCRIPTOR_UI
3000715 PUBCHEM_CID
2579 IUPHAR_LIGAND_ID
JI8Z5M7NA3 UNII
10493 RXNORM
2118 MMSL
2227 MMSL
5570 MMSL
d00388 MMSL
001398 NDDF
004578 NDDF
349829005 SNOMEDCT_US
387448009 SNOMEDCT_US
412605006 SNOMEDCT_US
433 INN_ID

Pharmaceutical products:

None